等待开盘 08-18 09:30:00 美东时间
-0.005
-0.01%
- Phase 3 CALIBRATE primary results were presented in an oral presentation at the 2026 ECE, demonstrating the rapid and durable benefit of encaleret across key clinical parameters in ADH1- All pre-specified primary and
05-12 19:32